secwatch.observer — SEC 8-K summary
======================================

Issuer:     NIKA PHARMACEUTICALS, INC (NIKA)
CIK:        0001145604
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001826466-24-000050
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nika Pharma acquires 40% of Nika Europe, now owns 80%; buys 4 technologies for $24,683
--------------------------------------------------------------------------------

- Merger with Nika BioTechnology gave Nika Pharma an additional 40% stake in Nika Europe Ltd, bringing total to 80%.
- Nika Europe Ltd acquired three generic drug technologies and one dietary supplement technology from AIPFPCB.
- Purchase price was 45,000 BGN (~$24,683), paid by officer Dimitar Savov, who is also general manager of Nika Europe.
- Acquired drug technologies: Menthyl Valerate 0.06g, Metamizole Sodium 500mg, Vinpocetine 10mg; supplement: Tribulus Terrestris extract 250mg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1145604/000182646624000050/0001826466-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1145604/000182646624000050/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001826466-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer